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Oral immunotherapy
Oral immunotherapy (OIT) is the only strategy that 
aims to achieve a ‘cure’ for the food allergic patient.[1] 
In most OIT protocols, small amounts of allergen 
are administered to patients in gradually increasing 
amounts, with the immediate goal of inducing desensitisation, and 
ultimately of achieving a state of tolerance.[2-4] With desensitisation, 
the treated patient manifests a decreased response to the ingested 
food allergens, but must continue to take daily food doses to maintain 
non-reactivity. In a state of tolerance, patients with food allergy may 
safely consume food without following a daily oral food regimen to 
maintain clinical non-reactivity.
OIT is a lengthy process (months - years) and consists of a series 
of dose escalations (usually in a controlled setting), with intervening 
maintenance periods (usually daily doses at home).[5]
The safety of OIT is problematic, with allergic reactions, including 
mild and severe reactions, developing in most patients. Long-term 
tolerance has not yet been adequately assessed.[6]
Owing to the many limitations of OIT, it is not yet recommended in 
routine clinical practice and should be restricted to the research setting. 
Anti-IgE antibody 
Currently, the most widely used anti-immunoglobulin E (IgE) 
antibody is omalizumab.[6] It is approved for treating aeroallergen-
sensitised children and adults (≥12 years of age in the USA, ≥6 years 
in Europe) with moderate-to-severe persistent asthma inadequately 
controlled with inhaled corticosteroids.
Studies using anti-IgE antibody in food allergy management 
are limited, but show promising results. Possible applications are 
for increasing the threshold of sensitivity to certain foods such as 
peanut,[7,8] and combined with OIT to enhance safety and rapidity of 
the OIT process.[9,10] Anti-IgE is however not yet licensed for use in 
food allergy.
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The process of oral immunotherapy (OIT) consists of a series of dose escalations with the immediate goal of inducing desensitisation and 
ultimately achieving a state of tolerance.
Owing to the limitations of OIT, including side-effects and lack of proven efficacy in long-term tolerance induction, it is not yet 
recommended in routine clinical practice and should be restricted to the research setting. 
Studies using anti-immunoglobulin E (IgE) antibody in food allergy management are limited, but show promising results. The possible 
applications are for increasing the sensitivity threshold to certain foods such as peanut, and also for use in combination with OIT to enhance 
safety and rapidity of the OIT process; however, anti-IgE is not yet licensed for use in food allergy.
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